Cargando…
Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma
Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced w...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158850/ https://www.ncbi.nlm.nih.gov/pubmed/32322199 http://dx.doi.org/10.3389/fphar.2020.00368 |
_version_ | 1783522569424470016 |
---|---|
author | Grégoire, Hélène Roncali, Loris Rousseau, Audrey Chérel, Michel Delneste, Yves Jeannin, Pascale Hindré, François Garcion, Emmanuel |
author_facet | Grégoire, Hélène Roncali, Loris Rousseau, Audrey Chérel, Michel Delneste, Yves Jeannin, Pascale Hindré, François Garcion, Emmanuel |
author_sort | Grégoire, Hélène |
collection | PubMed |
description | Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced with the particular case of brain tumors. The challenge here is major not only because the brain is the seat of our consciousness but also because of its isolation by the blood-brain barrier and the presence of a unique microenvironment that constitutes the central nervous system (CNS) with very specific constituent or patrolling cells. Much of the microenvironment is made up of immune cells or inflammation. Among these, tumor-associated macrophages (TAMs) are of significant interest as they are often involved in facilitating tumor progression as well as the development of resistance to standard therapies. In this review, the ubiquity of TAMs in GB will be discussed while the specific case of microglia resident in the brain will be also emphasized. In addition, the roles of TAMs as accomplices in the progression of GB and resistance to treatment will be presented. Finally, clinical trials targeting TAMs as a means of treating cancer will be discussed. |
format | Online Article Text |
id | pubmed-7158850 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71588502020-04-22 Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma Grégoire, Hélène Roncali, Loris Rousseau, Audrey Chérel, Michel Delneste, Yves Jeannin, Pascale Hindré, François Garcion, Emmanuel Front Pharmacol Pharmacology Glioblastoma (GB) is the most common and devastating form of brain cancer. Despite conventional treatments, progression or recurrences are systematic. In recent years, immunotherapies have emerged as an effective treatment in a number of cancers, leaving the question of their usefulness also faced with the particular case of brain tumors. The challenge here is major not only because the brain is the seat of our consciousness but also because of its isolation by the blood-brain barrier and the presence of a unique microenvironment that constitutes the central nervous system (CNS) with very specific constituent or patrolling cells. Much of the microenvironment is made up of immune cells or inflammation. Among these, tumor-associated macrophages (TAMs) are of significant interest as they are often involved in facilitating tumor progression as well as the development of resistance to standard therapies. In this review, the ubiquity of TAMs in GB will be discussed while the specific case of microglia resident in the brain will be also emphasized. In addition, the roles of TAMs as accomplices in the progression of GB and resistance to treatment will be presented. Finally, clinical trials targeting TAMs as a means of treating cancer will be discussed. Frontiers Media S.A. 2020-04-08 /pmc/articles/PMC7158850/ /pubmed/32322199 http://dx.doi.org/10.3389/fphar.2020.00368 Text en Copyright © 2020 Grégoire, Roncali, Rousseau, Chérel, Delneste, Jeannin, Hindré and Garcion http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Grégoire, Hélène Roncali, Loris Rousseau, Audrey Chérel, Michel Delneste, Yves Jeannin, Pascale Hindré, François Garcion, Emmanuel Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title_full | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title_fullStr | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title_full_unstemmed | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title_short | Targeting Tumor Associated Macrophages to Overcome Conventional Treatment Resistance in Glioblastoma |
title_sort | targeting tumor associated macrophages to overcome conventional treatment resistance in glioblastoma |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158850/ https://www.ncbi.nlm.nih.gov/pubmed/32322199 http://dx.doi.org/10.3389/fphar.2020.00368 |
work_keys_str_mv | AT gregoirehelene targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT roncaliloris targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT rousseauaudrey targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT cherelmichel targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT delnesteyves targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT jeanninpascale targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT hindrefrancois targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma AT garcionemmanuel targetingtumorassociatedmacrophagestoovercomeconventionaltreatmentresistanceinglioblastoma |